Real-world study tracks guselkumab staying power for psoriatic arthritis
Disease control
Not yet recruiting
This observational study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment for 1 to 2 years and why some stop. The goal is to understand real-world treatment patter…
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC